Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.35 |
| ▸ | GABRD | O14764 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15043867 | 1.00 | THRB (0.42) | THRBPOLBGAASLC6A1TSHR | |
| SCHEMBL3934728 | 1.00 | THRB (0.42) | THRBPOLBGAASLC6A1TSHR | |
| SCHEMBL29174145 | 0.93 | POLB (0.42) | THRBPOLBGAASLC6A1TSHR | |
| SCHEMBL51838 | 0.86 | — | — | |
| SCHEMBL3295484 | 0.86 | — | — | |
| SCHEMBL1666449 | 0.86 | — | — | |
| SCHEMBL29883233 | 0.86 | — | — | |
| SCHEMBL8891557 | 0.86 | TRIM24 (0.43) | THRBPOLBGAASLC6A1TSHR | |
| SCHEMBL28501013 | 0.84 | GABRP (0.41) | POLBGAATSHRLMNACYP2C19 | |
| SCHEMBL7893827 | 0.84 | THRB (0.43) | THRBSMN1; SMN2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146104-A | Novel carbonyl functionalized proton type ionic liquid and preparation method and application thereof | 南京大学 | 2024-06-07 | — | — | CN | claimed |
| CN-213132809-U | Movable low-temperature circulating pump for producing 3-carbonyl cyclohexanecarboxylic acid | 泰州精英化成医药科技有限公司 | 2021-05-07 | — | — | CN | claimed |
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2019-11-21 | — | — | US | claimed |
| EP-3078374-B1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | UNIV VANDERBILT (US) | 2019-06-19 | — | — | EP | claimed |
| EP-3078374-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2016-10-12 | — | — | EP | claimed |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-12-18 | — | — | US | claimed |
| EP-2768499-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | Vanderbilt University (US) | 2014-08-27 | — | — | EP | claimed |
| WO-2013059245-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | VANDERBILT UNIVERSITY (US) | 2013-04-25 | — | — | WO | claimed |
| EP-1987035-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | claimed |
| WO-2007093515-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN LA-ROCHE AG (CH) | 2007-08-23 | — | — | WO | claimed |
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | claimed |
| US-5488136-A | Process for the racemization of nonracemic 3-oxyocylopentane- or -hexanecarboxylic acids or their esters with C1 -C6 -alcohols | BOEHRINGER INGELHEIM KG (DE) | 1996-01-30 | — | — | US | claimed |
| EP-0407909-B1 | Process for the preparation of R-(+)-3-oxo cycloalkane carboxylic lower alkyl esters | BOEHRINGER INGELHEIM KG (DE) | 1994-11-02 | — | — | EP | claimed |
| EP-0407909-A1 | Process for the preparation of R-(+)-3-oxo cycloalkane carboxylic lower alkyl esters | BOEHRINGER INGELHEIM KG (DE) | 1991-01-16 | — | — | EP | claimed |
| JP-1063548-A | — | — | None | — | — | JP | disclosed |
| JP-1026533-A | — | — | None | — | — | JP | disclosed |
| EP-4698229-A1 | BISPECIFIC CYTOTOXICITY TARGETING CHIMERAS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2026-02-25 | — | — | EP | disclosed |
| JP-S6463548-A | 3,3-BIS(4-HYDROXYPHENYL)-CYCLOHEXANECARBOXYLIC ACID DERIVATIVE AND PRODUCTION THEREOF | MITSUI TOATSU CHEMICALS | 1989-03-09 | — | — | JP | disclosed |
| JP-S6426533-A | PRODUCTION OF 4'-HYDROXYBIPHENYL-3-CARBOXYLIC ACID | MITSUI TOATSU CHEMICALS | 1989-01-27 | — | — | JP | disclosed |
| US-4009181-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIRHEUMATIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350903-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | THRB 4035/4885POLB 2995/4885GAA 3839/4885 |
| US-20070191406-A1 | Heterocyclic antiviral compounds | CCR5, CX3CR1, CXCR1 | THRB 1306/4885POLB 2278/4885GAA 4126/4885 |
| US-20140371261-A1 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AKR1C3, AKR1C4, AKR1C1 | THRB 4250/4885POLB 3092/4885GAA 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.